News

In brief

BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7246.1358/b (Published 20 May 2000) Cite this as: BMJ 2000;320:1358

FDA backs Herceptin: The US Food and Drug Administration says that despite the recent findings that Genentech's breast cancer drug Herceptin (trastuzumab) was linked to the deaths of 15 patients and 47 adverse reactions, the drug's benefits still outweigh its risks.

Mobile phones might pose risk to children: The UK government is …

View Full Text

Sign in

Log in through your institution

Subscribe